Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

erythromycin 500mg

Uganda - English - National Drug Authority

sk age exports - erythromycin stearate - oral solid ordinary film-coated tablets - 250mg

Uganda - English - National Drug Authority

sk age exports - erythromycin ethyl succinate - oral liquid ordinary liquids - 125mg/5ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

s kant healthcare limited, india - erythromycin - tablets - 250

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

s k age exports, india - erythromycin stearate eq to erythromycin - tablets - 500

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

s k age exports, india - erythromycin stearate eq to erythromycin - suspension, oral - 125

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

s k age exports, india - erythromycin stearate eq to erythromycin - suspension, oral - 125mg/5ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

s k age exports, india - erythromycin stearate eq to erythromycin - suspension, oral - 125

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - erythromycin lactobionate, quantity: 1515 mg (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - indications as at 1 november 2002: oral erythromycin is not considered to be the antibiotic of choice in severely ill patients. erythrocin-i.v. (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae). respiratory tract infections due to mycoplasma pneumoniae. skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythrocin-i.v. (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.

United States - English - NLM (National Library of Medicine)

hospira, inc. - erythromycin lactobionate (unii: 33h58i7glq) (erythromycin - unii:63937kv33d) - erythromycin 500 mg in 10 ml - erythrocin lactobionate-iv (erythromycin lactobionate for injection, usp) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae  (diplococcus pneumoniae);  haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta-hemolytic streptococci);